Atrion Reports Second Quarter Results ALLEN,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Atrion Reports Second Quarter Results

ALLEN, TX--(Marketwired - Jul 31, 2013) - Atrion Corporation ( NASDAQ : ATRI ) today announced that for the second quarter of 2013 diluted earnings per share were up 7% and revenues were up 6% compared to the results for the second quarter of 2012.

Atrion's revenues for the quarter ended June 30, 2013 totaled $32.6 million compared with $30.7 million in the same period in 2012. On a diluted per share basis, earnings for the period increased to $3.22 as compared to $3.02 in the same period of last year. Net income for the second quarter totaled $6.5 million compared to $6.1 million in last year's second quarter.

Commenting on the Company's performance for the 2013 second quarter compared with the same period last year, David A. Battat, President and CEO, said, "As anticipated, sales of ophthalmic products showed a substantial increase in the quarter, with operations returning to full capacity as our customer's inventory adjustment cycle is now fully behind us. Cardiovascular products, and our "other" products category, primarily non-medical valves for the aviation and marine industries, both performed well with each showing a 7% increase in sales. Fluid delivery products were slightly below last year's level reflecting weak markets outside North America where a large share of this business originates." Mr. Battat added, "During the quarter we increased our cash and long and short term investments by $4.2 million after repurchasing 8,762 shares of stock at a cost of $1.9 million." Mr. Battat concluded, "Our commitment to organic growth is reflected in continued increases in spending on Research and Development, and higher depreciation charges for the expanding base of capital equipment needed to support future product introductions. Despite these ongoing increases, we expect double-digit growth in EPS for 2013." 

Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com .

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially. Such statements include, but are not limited to, Atrion's expectations regarding ongoing increases in spending on Research and Development and in depreciation charges and growth in EPS for 2013. Words such as "expects," "believes," "anticipates," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements involve risks and uncertainties. The following are some of the factors that could cause actual results or future events to differ materially from those expressed in or underlying our forward-looking statements: changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; the Company's ability to protect its intellectual property; changes in the prices of raw materials; changes in product mix; and intellectual property and product liability claims and product recalls. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission.

 
 
ATRION CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)
 
    Three Months Ended June 30,     Six Months Ended June 30,  
    2013     2012     2013     2012  
Revenues   $ 32,605     $ 30,689     $ 66,097     $ 59,929  
Cost of goods sold     16,971       16,016       34,754       31,427  
  Gross profit     15,634       14,673       31,343       28,502  
Operating expenses     6,139       5,706       12,448       11,592  
  Operating income     9,495       8,967       18,895       16,910  
                                 
Interest income     346       359       695       649  
Other income     --       --       --       2  
Income before income taxes     9,841       9,326       19,590       17,561  
Income tax provision     (3,335 )     (3,227 )     (6,450 )     (6,085 )
  Net income   $ 6,506     $ 6,099     $ 13,140     $ 11,476  
                                 
Income per basic share   $ 3.23     $ 3.03     $ 6.51     $ 5.70  
                                 
Weighted average basic shares outstanding     2,015       2,016       2,017       2,015  
                                 
                                 
Income per diluted share   $ 3.22     $ 3.02     $ 6.50     $ 5.67  
                                 
Weighted average diluted shares outstanding     2,019       2,019       2,021       2,023  
                                 
                                 
 
ATRION CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands)
 
    June 30,   Dec. 31,
ASSETS   2013   2012
    (Unaudited)    
Current assets:        
  Cash and cash equivalents   $ 20,269   $ 7,999
  Short-term investments     12,574     8,182
    Total cash and short-term investments     32,843     16,181
  Accounts receivable     17,126     13,054
  Inventories     25,183     23,779
  Prepaid expenses and other     2,300     3,110
  Deferred income taxes     623     623
    Total current assets     78,075     56,747
                 
Long-term investments     20,124     28,433
             
Property, plant and equipment, net     57,787     59,268
Other assets     11,355     11,362
             
    $ 167,341   $ 155,810
             
             
LIABILITIES AND STOCKHOLDERS' EQUITY            
             
Current liabilities     10,362     7,208
Line of credit     --     --
Other non-current liabilities     13,331     13,774
Stockholders' equity     143,648     134,828
             
    $ 167,341   $ 155,810
             
             

Contact: Jeffery Strickland Vice President and Chief Financial Officer (972) 390-9800

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 50

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 145

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 25

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 159

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 83

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 155

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 10

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 19

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 101

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 104

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading

Top 5 Most Recently Viewed Articles

Volta Finance Limited: Monthly Insights and Performance Metrics

Updated Category News Views 252

Understanding Volta Finance Limited's Performance for September 2025 Volta Finance Limited (VTA / VTAS) recently released its monthly report for September 2025. This report sheds light on the performance metrics that have shaped the company's strategies and outcomes over the past month, illustrating how they navigate an ever-changing financial landscape. Performance...

Continue Reading
Class Actions Alert: Understanding Investor Rights for SOC, LMT, NVO, LINE

Updated Category News Views 213

Understanding Class Action Lawsuits for Shareholders In today’s fast-paced investment world, shareholders must stay informed about class action lawsuits that may affect their investments. A recent alert highlights key class actions involving four publicly-traded companies, offering investors a glimpse into their rights and potential next steps. Sable Offshore Corp....

Continue Reading
Exploring ONCT-534: New Insights on Advanced Prostate Cancer

Updated Category News Views 202

Recent Updates on ONCT-534 for Advanced Prostate Cancer Oncternal Therapeutics, Inc. (NASDAQ: ONCT) has unveiled encouraging updates regarding its investigational therapy, ONCT-534, specifically targeting relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). This exciting development stems from the company’s ongoing Phase 1/2 Study, known as...

Continue Reading
GDS Holdings Celebrates Successful IPO of C-REIT in Shanghai

Updated Category News Views 197

GDS Holdings Completes C-REIT IPO on Shanghai Stock Exchange Shanghai, China — GDS Holdings Limited (NASDAQ: GDS; HKEX: 9698), a prominent developer and operator of high-performance data centers, has recently triumphantly finished its initial public offering (IPO) for the China REIT (C-REIT) on the Shanghai Stock Exchange. This achievement marks a significant milestone...

Continue Reading
Surge in Russian Stocks: MOEX Russia Index Reaches New Heights

Updated Category News Views 255

Russian Stocks Experience Notable Gains In recent trading sessions, Russian stocks showed significant upward movement, showcasing the resilience of various sectors within the economy. With the MOEX Russia Index closing higher, this is an indication of investor optimism and market recovery. Key Contributors to Market Gains Sector Performance Highlights The increase in the...

Continue Reading